Clinical Trial Update: Drug-screening in AML at Relapse for Targeted Treatment [NA]

View source ↗

Summary

This document reports that the clinical trial NCT05732688 evaluating drug-screening at relapse for targeted treatment in acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Snippet

Sponsor: Insel Gruppe AG, University Hospital Bern | Conditions: AML | NA | Status: COMPLETED